We’ve issued an urgent landmark trade alert for a new crypto wonder. So, I decided to give you this heads-up before it’s too late. It’s urgent because it’s what we consider “The #1 Crypto for the AI World.”

Learn more about it by watching THIS NOW.

David Jakeman Biography and Net Worth

Insider of Chimerix

Executive Director-Finance & Accounting, Chimerix, Inc.
Currently, David Jakeman occupies the position of Executive Director-Finance & Accounting at Chimerix, Inc.

Mr. Jakeman received an undergraduate degree and a graduate degree from The University of North Carolina at Charlotte.

What is David Jakeman's net worth?: The estimated net worth of David Jakeman is at least $396,861.92 as of February 14th, 2024. Mr. Jakeman owns 141,232 shares of Chimerix stock worth more than $396,862 as of December 18th. This net worth evaluation does not reflect any other assets that Mr. Jakeman may own. Learn More about David Jakeman's net worth.
How old is David Jakeman?: Mr. Jakeman is currently 46 years old. There are 5 older executives and no younger executives at Chimerix. The oldest executive at Chimerix is Dr. Allen S. Melemed M.B.A., M.D., Chief Medical Officer, who is 60 years old. Learn More on David Jakeman's age.
How do I contact David Jakeman?: The corporate mailing address for Mr. Jakeman and other Chimerix executives is 2505 MERIDIAN PARKWAY SUITE 100, DURHAM NC, 27713. Chimerix can also be reached via phone at (919) 806-1074 and via email at [email protected]. Learn More on David Jakeman's contact information.
Has David Jakeman been buying or selling shares of Chimerix?: David Jakeman has not been actively trading shares of Chimerix within the last three months. Most recently, David Jakeman sold 2,660 shares of the business's stock in a transaction on Wednesday, February 14th. The shares were sold at an average price of $1.04, for a transaction totalling $2,766.40. Following the completion of the sale, the vice president now directly owns 141,232 shares of the company's stock, valued at $146,881.28. Learn More on David Jakeman's trading history.
Who are Chimerix's active insiders?: Chimerix's insider roster includes David Jakeman (Insider), Robert Meyer (Director), and Fred Middleton (Director). Learn More on Chimerix's active insiders.
Are insiders buying or selling shares of Chimerix?: In the last twelve months, insiders at the biopharmaceutical company sold shares 4 times. They sold a total of 7,629 shares worth more than $7,664.31. The most recent insider tranaction occured on August, 8th when CEO Michael T Andriole sold 1,285 shares worth more than $1,066.55. Insiders at Chimerix own 13.1% of the company. Learn More about insider trades at Chimerix.
Information on this page was last updated on 8/8/2024.

David Jakeman Insider Trading History at Chimerix

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction
2/14/2024	Sell	2,660	$1.04	$2,766.40	141,232
9/28/2023	Sell	3,610	$0.99	$3,573.90	133,142
1/26/2023	Sell	3,230	$1.76	$5,684.80	136,752
9/29/2022	Sell	4,400	$1.86	$8,184.00	127,532
2/4/2022	Sell	3,300	$5.56	$18,348.00
9/30/2021	Sell	4,590	$6.19	$28,412.10
4/5/2021	Sell	1,284	$9.68	$12,429.12
1/28/2021	Sell	3,211	$8.61	$27,646.71	96,906
10/2/2020	Sell	4,270	$2.48	$10,589.60

David Jakeman Buying and Selling Activity at Chimerix

Chimerix Company Overview

Chimerix, Inc., a biopharmaceutical company, develops medicines to improve and extend the lives of patients facing deadly diseases. Its pipeline products include ONC201 a program that is in Phase 3 clinical trial for treating patients with H3 K27M-mutant diffuse glioma, as well as in Phase 2 clinical trial for the treatment of rare neuroendocrine tumors; and ONC206, an imipridone, Dopamine Receptor D2 (DRD2) antagonist, and caseinolytic protease P (ClpP) agonist, which is in Phase 1 clinical trial for adult and pediatric patients with primary central nervous system tumors. The company also develops ONC212, an imipridone agonist of the orphan G protein-coupled receptors (GPCR) tumor suppressor GPR132, as well as ClpP for oncology indications; and CMX521, a nucleoside analog antiviral drug candidate for the treatment of SARS-CoV-2. It has license agreement with SymBio Pharmaceuticals to develop and commercialize TEMBEXA for human diseases other than orthopoxviruses, including smallpox. Chimerix, Inc. was incorporated in 2000 and is headquartered in Durham, North Carolina.

Today's Range

Now: $2.81

$2.75

$3.02

50 Day Range

MA: $1.11

$0.83

$2.98

2 Week Range

Now: $2.81

$0.75

$3.39

Volume

2,118,960 shs

Average Volume

1,257,564 shs

Market Capitalization

$252.72 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.02

Is Starlink Set For The Largest IPO In History?

From Paradigm Press | Ad

He turned PayPal from a tiny, off-the-radar startup… to a massive $64 billion giant. Then, he did it again with Tesla… which is up more than 19,500% since 2010. For perspective, that turns $100 invested into almost $20,000!

Click here now for the urgent details.

David Jakeman Biography and Net Worth

What is David Jakeman's net worth?

How old is David Jakeman?

How do I contact David Jakeman?

Has David Jakeman been buying or selling shares of Chimerix?

Who are Chimerix's active insiders?

Are insiders buying or selling shares of Chimerix?